Doxycycline
- Generic Name
- Doxycycline
- Brand Names
- Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24N2O8
- CAS Number
- 564-25-0
- Unique Ingredient Identifier
- 334895S862
- Background
Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is...
- Indication
Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:
It is also used to treat infections caused by the following gram-negative microorganisms:
- Associated Conditions
- Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection
- Associated Therapies
- -
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 250
- Registration Number
- NCT05382208
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Temple University, Philadelphia, Pennsylvania, United States
🇺🇸University of California San Diego, San Diego, California, United States
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
- Conditions
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT05343455
- Locations
- 🇺🇸
Clinical Trial Site 14, Miami, Florida, United States
🇺🇸Clinical Trial Site 05, Miramar, Florida, United States
🇺🇸Clinical Trial Site 08, Clarksville, Indiana, United States
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- Conditions
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 323
- Registration Number
- NCT05296629
- Locations
- 🇺🇸
Clinical Trial Site 25, San Diego, California, United States
🇺🇸Clinical Trial Site 13, Houston, Texas, United States
🇺🇸Clinical Trial Site 02, Indianapolis, Indiana, United States
Lefamulin for M. Genitalium Treatment Failures
- Conditions
- Interventions
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 12
- Registration Number
- NCT05111002
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Collaborative Urological Prosthetics Investigation Directive Research Group
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 800
- Registration Number
- NCT05100654
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Helicobacter Pylori Eradication and Follow-up
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 4447
- Registration Number
- NCT05061732
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Tetracycline Versus Doxycycline for HP Rescue Therapy
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 242
- Registration Number
- NCT05018923
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Skin Microbiome Profile in Hailey-Hailey Disease
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT05007223
- Locations
- 🇰🇷
GangnamSeveracne Hospital, Seoul, Korea, Republic of
Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT04860505
- Locations
- 🇺🇸
Hope Clinic, Atlanta, Georgia, United States
Clinical Trial of Doxycycline VS BPG for Early Syphilis (SY-DOXY)
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 200
- Registration Number
- NCT04838717
- Locations
- 🇫🇷
Hôpital Cochin, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.